Thomas E. Witzig

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

Gregory A. Wiseman, Christine A. White, Michael Stabin et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 234 citations

Medicine, Oncology, Pharmacotherapy +15

Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma

Thomas E. Witzig, Robert A. Kyle, W. Michael O’Fallon et al. · British Journal of Haematology · 1994 · 94 citations

Medicine, Hematology, Pathology +17

Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis

Morie A. Gertz, Martha Q. Lacy, John A. Lust et al. · American Journal of Hematology · 1999 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Thrombosis Related to the Use of L-Asparaginase in Adults with Acute Lymphoblastic Leukemia: a Need to Consider Coagulation Monitoring and Clotting Factor Replacement

Steven R. Alberts, Mary E. Bretscher, John C. Wiltsie et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1999 · 31 citations

Medicine, Hematology, Oncology +17